USFDA Inspection of Shilpa Medicare Limited at Unit VI, Dabaspet, Bengaluru
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
USFDA conducted a Pre-Approval Inspection (PAI) at Shilpa Medicare's Unit VI facility in Dabaspet, Bengaluru from May 25-29, 2026. The inspection concluded with the issuance of FDA Form 483 containing 5 procedural observations. The company clarified that none of the observations are repeat findings or related to data integrity issues. Unit VI has a strong regulatory track record with Voluntary Action Indicated (VAI) status from a previous USFDA GMP inspection, along with approvals from EMA, SFDA, MHRA, and TGA. The facility manufactures oral dispersible films and transdermal patches. Shilpa Medicare stated it does not expect any material impact on current business operations or existing supplies, and will respond comprehensively to the observations within the stipulated timeframe.
The inspection result appears manageable with procedural observations rather than serious compliance violations, suggesting limited near-term risk to the stock. However, investors should monitor the company's response to USFDA to ensure timely resolution.